SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile (SV95C) for Duchenne Muscular Dystrophy

EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials SV95C is an objective, real-world digital ambulation measure of top performance, informing more confident treatment decision-making and streamlining drug…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.